Research analysts covering Biophytis.
Recent press releases and 8-K filings for BPTSY.
Biophytis Secures Brazilian Public Funding and Clinical Partnerships for Obesity Phase 2 Trial
BPTSY
New Projects/Investments
- Biophytis has secured non-dilutive public funding from EMBRAPII in Brazil for its OBA Phase 2 trial of BIO101, which targets muscle wasting associated with obesity.
- The company also established agreements with two leading Brazilian clinical research centers, FARMAVAX-UFMG and FMRP-USP, which are crucial for recruiting 122 of the 164 planned patients for the OBA trial.
- These developments are expected to financially de-risk the trial, accelerate operations, and enhance the program's scientific and strategic credibility, reducing the company's cash requirements.
Sep 15, 2025, 3:54 PM
Biophytis Unveils Phase 3 Sarcopenia Trial Strategy
BPTSY
New Projects/Investments
- Biophytis SA has unveiled its Phase 3 SARA trial strategy for BIO101, targeting age-related sarcopenia, with plans to recruit 932 patients primarily in Asia (China and Japan) and Europe.
- This trial is designed to be the first Phase 3 ever conducted in sarcopenia, addressing a substantial unmet medical need and commercial market estimated at over 65 million patients across China, Japan, and Europe.
- The financing for the Phase 3 program will be achieved through collaborations with regional pharmaceutical companies and local investors in Asia, including non-dilutive private financing stakeholders.
- Trial initiation is expected in the coming months in Europe, with formal initiation in China and Japan anticipated in 2026 after regulatory filings and partnership finalization.
Sep 11, 2025, 2:59 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more